OMEQ MEDICAL
- Jul 20
- 3 min
Omeq Medical received FDA regulatory clearance ("FDA") for its EPiFINDER.
Exciting news on our novel solution that has the potential to become the standard of care for safer epidural injections.
1070
top of page
SMART DEVICE FOR EPIDURAL INJECTIONS
OMEQ Medical Smart Device for Epidural Injections
Home: Welcome
EPIFINDER
Accurately Identifies the Epidural Space
MEASURES TISSUE RESISTANCE AT THE NEEDLE TIP
ENABLES INDEPENDENT OBJECTIVE SIGNAL TO CONFIRM CORRECT NEEDLE PLACEMENT
Home: Our Technology
Integrates with standard kit and works simultaneously with LOR technique
Independent signal ensures correct placement
Easy to operate
Home: Infographics
WHY WE DEVELOPED THE EPIFINDER
Home: Text
The current technique to administer epidurals, loss of resistance (“LOR”), is a subjective technique:
•Needle placement is based on tactile feedback and feel
•The technique requires extensive expertise
•Success is operator dependent
Home: Quote
A $3 BILLION MARKET SIZE
40M Epidural injections annually
9.3% Compound annual growth rate
Home: Image
MEET OUR TEAM
Lior Margalit
CEO
Maya Shick
Clinical Director
Jonathan Harari
QA Consultant
Carl Rickenbaugh
Chairman
Home: Testimonials
Home:Blog
CONTACT
Misgav Business Park, 17 T’chelet Street M.P. Misgav, 2017400
• Israel
+972-54-431-5304
Home: Contact
bottom of page